WOBURN, Mass.--(BUSINESS WIRE)--Spear Bio Inc., a biotechnology company enabling the measurement of protein molecules down to dozens of copies with ubiquitous qPCR equipment, announced the successful closing of its $45 million Series A financing. The oversubscribed round was co-led by Foresite Capital and Bio-Techne Corporation, with additional participation from existing investors including Maverick Ventures, Yonjin Capital and CDH Investments.

马萨诸塞州沃本市（商业新闻短讯）--生物技术公司Spear Bio Inc.宣布成功完成其4500万美元的a系列融资，该公司能够使用无处不在的qPCR设备对蛋白质分子进行多达数十个拷贝的测量。这轮超额认购由福雷斯特资本（Foresite Capital）和生物技术公司（Bio-Techne Corporation）共同牵头，现有投资者（包括Maverick Ventures、Yonjin Capital和CDH Investments）也参与了此次认购。

Vikram Bajaj, Managing Director of Foresite Capital, has joined the company’s Board of Directors..

Forestite Capital董事总经理Vikram Bajaj已加入公司董事会。。

Leveraging standard qPCR instruments, with a three-step wash-free workflow, Spear Bio's patented Successive Proximity Extension Amplification Reaction (SPEAR) technology precisely measures protein biomarkers at the attomolar level without high-affinity antibodies from less than 1 microliter sample volume, 100 times less than the typical sample volume required for immunoassays..

利用标准qPCR仪器，采用三步免清洗工作流程，Spear Bio获得专利的连续邻近延伸扩增反应（Spear）技术可以在不到1微升样品体积的情况下精确测量阿摩尔水平的蛋白质生物标志物，而不需要高亲和力抗体，比免疫测定所需的典型样品体积少100倍。。

“We are grateful for the strong support from such an exceptional group of investors. Foresite has been instrumental in the success of multiple game-changing life science tool and diagnostics companies, and Bio-Techne is a global industry leader, providing solutions for scientific advancements and healthcare breakthroughs.” said Dr.

“我们感谢如此杰出的投资者群体的大力支持。Forestite为多家改变游戏规则的生命科学工具和诊断公司的成功做出了贡献，Bio-Techne是全球行业领导者，为科学进步和医疗保健突破提供解决方案。”Dr。

Feng Xuan, co-founder and CEO of Spear Bio. “Their investment is a strong endorsement of SPEAR technology and the company’s vision. This funding will allow us to accelerate our assay menu expansion and commercial offerings to solve challenges in protein research and early disease diagnostics.”.

Spear Bio联合创始人兼首席执行官冯轩表示：“他们的投资是对Spear技术和公司愿景的有力支持。这笔资金将使我们能够加速分析菜单的扩展和商业产品的提供，以解决蛋白质研究和早期疾病诊断方面的挑战。”。

'Foresite Capital is excited to support Spear Bio's transformative mission,' said Dr. Vikram Bajaj, Managing Director of Foresite Capital. 'I believe SPEAR technology has immense potential to advance neurodegenerative disease research and diagnostics by providing robust and scalable solutions for low-abundant protein biomarker measurement.

Forestite Capital董事总经理Vikram Bajaj博士说，Forestite Capital很高兴支持Spear Bio的变革使命我相信，SPEAR技术通过为低丰度蛋白质生物标志物测量提供强大且可扩展的解决方案，在推进神经退行性疾病研究和诊断方面具有巨大潜力。

I look forward to contributing to Spear Bio’s growth as a board member.'.

我期待着为Spear Bio作为董事会成员的成长做出贡献。”。

“We are excited to invest in Spear Bio,” said Kim Kelderman, President and CEO of Bio-Techne. “Spear Bio’s ultra-sensitive detection technology offers significant advantages over conventional immunoassay and next-gen proteomic technologies, enabling the quantification of mere dozens of protein molecules in a sample.

Bio-Techne总裁兼首席执行官金·凯尔德曼（KimKelderman）表示：“我们很高兴投资Spear Bio。”。“与传统免疫分析和下一代蛋白质组学技术相比，Spear Bio的超灵敏检测技术具有显着优势，可以对样品中的数十种蛋白质分子进行定量。

This level of sensitivity unlocks several challenging applications and high-growth markets, including early diagnosis of neurodegenerative diseases. Importantly, Spear Bio’s assays run on qPCR equipment, which is routinely found in research and clinical facilities, representing an existing installed base to run these groundbreaking assays.”.

这种敏感性水平开启了几个具有挑战性的应用和高增长市场，包括神经退行性疾病的早期诊断。重要的是，Spear Bio的检测运行在qPCR设备上，该设备通常在研究和临床设施中找到，代表了运行这些开创性检测的现有安装基础。”。

Spear Bio is presenting its technology and applications to neurology at the Alzheimer’s Association International Conference (AAIC) in Philadelphia from July 28th to August 1, at Booth #740 on the exhibit floor and Poster presentation #279 on Wednesday, July 31.

Spear Bio将于7月28日至8月1日在费城举行的阿尔茨海默氏病协会国际会议（AAIC）上展示其在神经病学方面的技术和应用，7月31日（星期三）将在展厅第740号展位和第279号海报上展示。

About Spear Bio

关于Spear Bio

Spear Bio – founded in 2021 and headquartered in Woburn, Massachusetts – is an innovative leader in providing scalable solutions for ultra-sensitive protein biomarker measurements. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar level from sub-microliter sample volume.

Spear Bio成立于2021年，总部位于马萨诸塞州沃本，是为超灵敏蛋白质生物标志物测量提供可扩展解决方案的创新领导者。Spear Bio的专有技术，连续邻近延伸扩增反应（Spear），采用独特的双因素认证机制，从亚微升样品体积精确测量阿摩尔水平的蛋白质生物标志物。

Spear Bio is focused on leveraging its technology’s unprecedented sensitivity to transform protein research and early disease diagnosis..

Spear Bio专注于利用其技术前所未有的敏感性来转化蛋白质研究和早期疾病诊断。。

For further information, please visit www.spear.bio or email info@spear.bio.

欲了解更多信息，请访问www.spear.bio或发送电子邮件info@spear.bio.